Horizon Therapeutics Announces Corporate Relocation to the Chicago Area

PALO ALTO, Calif., July 31 /PRNewswire/ -- Horizon Therapeutics, Inc., a
privately held biopharmaceutical company, today announced that it will move
its corporate headquarters from Palo Alto, Calif. to the Chicago, Ill., area.
"The relocation will help us continue growing, extend our opportunities
for partnerships and conduct business in one of the most dynamic markets in
the country," said Timothy P. Walbert, president and chief executive officer
of Horizon. "Chicago has all the elements to become a major life-science hub,
but it's still rivaled by its bi-coastal counterparts. We wanted to relocate
here to be an integral part of the market growth as well as leverage the
existing market opportunities to grow our business."
The company will begin operations in its new headquarters in early August
at the Illinois Science and Technology Park in Skokie, Ill., which formerly
housed the Searle and then subsequently Pharmacia and Pfizer research and
development offices. Horizon has approximately 50 full-time employees and
consultants.
Mr. Walbert, who was recently named president and chief executive officer
of Horizon and has approximately 20 years of proven experience launching and
commercializing blockbuster drugs in the pain and arthritis fields, is
focusing the Company's efforts on meeting the needs of arthritis and pain
sufferers, specifically with its investigational compound HZT-501, a novel
proprietary formulation of ibuprofen combined with famotidine in a single pill
currently in Phase 3 clinical trials. Because approximately 25 percent of
NSAID users may develop stomach ulcers, HZT-501 may offer patients effective
pain relief with the confidence of GI-protection. Horizon expects to have
data from the HZT-501 Phase 3 trials in fourth quarter of this year.
About Horizon Therapeutics
Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company
focused on the development and commercialization of therapies for the
treatment of mild-to-moderate pain and arthritis. Horizon's clinical
portfolio includes innovative combination therapies in early- and late-stage
development that are designed to improve safety, efficacy and patient
compliance. For more information about the company and its products, please
visit http://www.horizontherapeutics.com.
SOURCE Horizon Therapeutics, Inc.

Geoff Curtis of WeissComm Partners, Inc., +1-312-284-4701,
gcurtis@wcpglobal.com, for Horizon Therapeutics, Inc.